Nauman Toor Joins Xhale, Inc.'s Board of Directors

GAINESVILLE, Fla. - July 31, 2014 - PRLog -- The Board of Directors of Xhale, Inc. today announced the appointment of Nauman (Nick) Toor as a board member of Xhale, Inc.

Mr. Toor is a Co-Founder and the Chief Investment Officer of Luzich Partners, a multi-strategy investment fund with a focus on both public and private equity investments. Previously, Mr. Toor was Founder and Chief Investment Officer of BlackRoot Capital, an investment fund focused on small-cap public equities and special situations.

Prior to BlackRoot Capital, Mr. Toor served as Managing Director of Jefferies & Company Inc., from April 2001 to December 2006. He also served as Head of Media Investment Banking at Jefferies, where he began working in 1994, and guided Jefferies’ growth and strategic direction as a member of the Investment Banking Management Group.    Mr. Toor began his career in investment banking with Kidder Peabody & Co. in New York in 1990.

Mr. Toor holds a Bachelor of Arts degree in Economics from Ohio Wesleyan University and a Masters in Business Administration from Harvard Business School.


About Xhale

Xhale is a medical technology company developing and commercializing patient-centric monitoring solutions for the healthcare industry. Xhale is focused on developing two broad technology platforms. Through its Xhale Smart subsidiary, Xhale is developing a medication adherence monitoring technology - the SMART® Adherence System - designed to verify, monitor, report, and improve adherence to medication regimens in clinical trials. The SMART® Adherence System is the only technology that offers definitive and noninvasive monitoring of medication adherence in near real-time, utilizing exhaled breath to confirm that medication has been taken as directed. Xhale Smart is an emerging leader in patient-centric monitoring solutions for medication adherence. Through its Xhale Assurance subsidiary, Xhale is developing a patient monitoring technology - the Assurance® platform - designed to improve and expand the use of conventional pulse oximetry used in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured. Xhale’s first product based on this technology, the Assurance® Alar One-Sense™ pulse oximetry sensor, received marketing clearance in the United States. The Assurance® Alar One-Sense™ pulse oximetry sensor is a disposable sensor placed on a patient’s nasal ala which transmits heart rate and blood oxygenation information to an oximetry monitor. For more information, please visit or contact the company at or 352-371-8488.

Xhale Inc
Email:*** Email Verified
Tags:Patient Adherence, Medical Technology, Medication Monitoring, Personalized Medicine, Pulse Oximetry
Industry:Biotech, Medical
Location:Gainesville - Florida - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Xhale, Inc. News
Daily News
Weekly News

Daily News
Weekly News
PTC News

Jul 31, 2014 News

Like PRLog?
Click to Share